Johnson & Johnson undershoots full-year earnings guidance

New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today’s annual earnings call, but slightly undershot with its adjusted earnings results. The company reported a reported 6.5% year-on-year growth in sales of $85.2 billion but the full-year earnings per share (EPS) depicted a different trend, decreasing by 15.3% to $5.20 a share. This decline was primarily due to a special one-time charge incurred in the first quarter. On an adjusted basis, EPS increased by 11.1% ...